FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274474344> ?p ?o ?g. }

• W2274474344 endingPage "1077" @default.
• W2274474344 startingPage "1077" @default.
• W2274474344 abstract "1077 Background: KSP is a mitotic kinesin essential for cell cycle progression. Ispinesib, a selective KSP inhibitor, blocks mitotic spindle assembly with cell cycle arrest in mitosis and subsequent cell death. On a q21d schedule, the MTD was 18 mg/m 2 . In a phase II trial of ispinesib dosed at 18 mg/m 2 q21d in patients (pts) with advanced breast cancer after anthracycline and taxane failure, the response rate was 4/45 (9%). This trial evaluates ispinesib given on d1 and d15 q28d, thus increasing dose density. Methods: In phase I of this phase I/II trial, DLT and MTD of ispinesib given d1 and d15 q28d will be determined. Eligibility criteria: advanced breast cancer; no prior chemotherapy (CT) except neoadjuvant or adjuvant and ≥ 1 yr elapsed since CT; no CNS metastases; ECOG 0–1. This is a standard 3+3 dose escalation trial design, starting at 10 mg/m 2 and escalating based on tolerability in cycle (cy) 1. Pharmacokinetic data are collected in cy 1. Results: Phase I of the trial is ongoing. 16 pts were treated at 3 dose levels: 10 (n = 3), 12 (n = 6), and 14 mg/m 2 (n = 7). 9 pts were stage IV; 11 were chemo-naïve; 5 had prior anthracycline and/or taxane; 4 were HER-2+ and 5 ER-, PR-, HER-2-. The most frequent toxicity was neutropenia. 88% of pts in cy 1 (grade 3/4 in 75%; no febrile neutropenia). Mild GI toxicity occurred in <37.5% of pts. There was no neuropathy or alopecia. At the 14 mg/m 2 dose level, 2/7 pts had DLTs of transient grade 3 AST and ALT increases after cy 1 d15 dosing; both without increases upon retreatment; 1 in a pt with liver metastases; neither pt had significant increases in alkaline phosphatase or bilirubin. The 12 mg/m 2 cohort was expanded to 6 pts without DLT. 3 pts had partial response (after 1 [n = 1] and 4 [n = 2] cy, respectively); 1 confirmed and ongoing after 8+ cy; 4 pts had stable disease ≥4 mo. Conclusions: Ispinesib appears to be well tolerated on a q14d dosing schedule at doses tested to date. A dose-density equal to that given in the prior phase II trial (0.86 mg/m 2 /d) was tolerated with the q14d schedule with preliminary evidence of efficacy. Further exploration of the 14 mg/m 2 dose level is planned. [Table: see text]" @default.
• W2274474344 created "2016-06-24" @default.
• W2274474344 creator A5009229150 @default.
• W2274474344 creator A5011514688 @default.
• W2274474344 creator A5012382157 @default.
• W2274474344 creator A5014853503 @default.
• W2274474344 creator A5014902835 @default.
• W2274474344 creator A5033540310 @default.
• W2274474344 creator A5052159944 @default.
• W2274474344 creator A5052880954 @default.
• W2274474344 creator A5057810162 @default.
• W2274474344 date "2009-05-20" @default.
• W2274474344 modified "2023-09-26" @default.
• W2274474344 title "A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence" @default.
• W2274474344 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.1077" @default.
• W2274474344 hasPublicationYear "2009" @default.
• W2274474344 type Work @default.
• W2274474344 sameAs 2274474344 @default.
• W2274474344 citedByCount "0" @default.
• W2274474344 crossrefType "journal-article" @default.
• W2274474344 hasAuthorship W2274474344A5009229150 @default.
• W2274474344 hasAuthorship W2274474344A5011514688 @default.
• W2274474344 hasAuthorship W2274474344A5012382157 @default.
• W2274474344 hasAuthorship W2274474344A5014853503 @default.
• W2274474344 hasAuthorship W2274474344A5014902835 @default.
• W2274474344 hasAuthorship W2274474344A5033540310 @default.
• W2274474344 hasAuthorship W2274474344A5052159944 @default.
• W2274474344 hasAuthorship W2274474344A5052880954 @default.
• W2274474344 hasAuthorship W2274474344A5057810162 @default.
• W2274474344 hasConcept C121608353 @default.
• W2274474344 hasConcept C126322002 @default.
• W2274474344 hasConcept C126894567 @default.
• W2274474344 hasConcept C141071460 @default.
• W2274474344 hasConcept C143998085 @default.
• W2274474344 hasConcept C197934379 @default.
• W2274474344 hasConcept C2775930923 @default.
• W2274474344 hasConcept C2776694085 @default.
• W2274474344 hasConcept C2776802502 @default.
• W2274474344 hasConcept C2777063308 @default.
• W2274474344 hasConcept C2777511904 @default.
• W2274474344 hasConcept C2778375690 @default.
• W2274474344 hasConcept C2778850193 @default.
• W2274474344 hasConcept C530470458 @default.
• W2274474344 hasConcept C71924100 @default.
• W2274474344 hasConcept C90924648 @default.
• W2274474344 hasConcept C98274493 @default.
• W2274474344 hasConceptScore W2274474344C121608353 @default.
• W2274474344 hasConceptScore W2274474344C126322002 @default.
• W2274474344 hasConceptScore W2274474344C126894567 @default.
• W2274474344 hasConceptScore W2274474344C141071460 @default.
• W2274474344 hasConceptScore W2274474344C143998085 @default.
• W2274474344 hasConceptScore W2274474344C197934379 @default.
• W2274474344 hasConceptScore W2274474344C2775930923 @default.
• W2274474344 hasConceptScore W2274474344C2776694085 @default.
• W2274474344 hasConceptScore W2274474344C2776802502 @default.
• W2274474344 hasConceptScore W2274474344C2777063308 @default.
• W2274474344 hasConceptScore W2274474344C2777511904 @default.
• W2274474344 hasConceptScore W2274474344C2778375690 @default.
• W2274474344 hasConceptScore W2274474344C2778850193 @default.
• W2274474344 hasConceptScore W2274474344C530470458 @default.
• W2274474344 hasConceptScore W2274474344C71924100 @default.
• W2274474344 hasConceptScore W2274474344C90924648 @default.
• W2274474344 hasConceptScore W2274474344C98274493 @default.
• W2274474344 hasIssue "15_suppl" @default.
• W2274474344 hasLocation W22744743441 @default.
• W2274474344 hasOpenAccess W2274474344 @default.
• W2274474344 hasPrimaryLocation W22744743441 @default.
• W2274474344 hasRelatedWork W1966468630 @default.
• W2274474344 hasRelatedWork W1982876272 @default.
• W2274474344 hasRelatedWork W2005952319 @default.
• W2274474344 hasRelatedWork W2020150632 @default.
• W2274474344 hasRelatedWork W2053822401 @default.
• W2274474344 hasRelatedWork W2092771806 @default.
• W2274474344 hasRelatedWork W2240453727 @default.
• W2274474344 hasRelatedWork W2525148581 @default.
• W2274474344 hasRelatedWork W2999712386 @default.
• W2274474344 hasRelatedWork W3030794620 @default.
• W2274474344 hasVolume "27" @default.
• W2274474344 isParatext "false" @default.
• W2274474344 isRetracted "false" @default.
• W2274474344 magId "2274474344" @default.
• W2274474344 workType "article" @default.